Standard treatment of localized muscle-invasive bladder cancer (MIBC) is neoadjuvant chemotherapy (NAC) followed by radical cystectomy (RC), but ∼50% of patients relapse within 2 years. Adjuvant immunotherapy is currently administered based on pathology and clinical assessment in high-risk patients only, potentially resulting in under- and overtreatment.
ctDNA-Guided Immunotherapy following Radical Cystectomy for Muscle-Invasive Bladder Cancer: Results from the TOMBOLA Trial
Annals of Oncology | | L. Dyrskjøt, K. Birkenkamp-Demtröder, I. Nordentoft, T. Strandgaard, S.V. Lindskrog, R.V. Milling, S.K. Körner, S.B. Brandt, M. Knudsen, T.G. Andreasen, C.F. Hansen, P. Lamy, G. Lam, L.H. Dohn, K. Fabrin, A. Carus, A.C. Petersen, U.N. Joensen, H. Pappot, P.S. Holt, N.V. Jensen, M. Agerbæk, J.B. Jensen
Topics: blood-cancer, bladder-cancer, immunotherapy, targeted-therapy, chemotherapy, research